York Pharma (YRK.L) - a second shot at the Big Prize


	User Name	Password


	back to homepage York Pharma (YRK.L) - a second shot at the Big Prize AIM: YRK.L Coverage by Objective Capital Questions? Contact our analyst Click to download our initiation report on this company (44 pages, this is a 1.1m download) Recent comments on this company York Pharma (YRK.L) - forced to return Flammazine/Flammacerium to Solvay Jan 14, 2009 York Pharma (YRK.L) - acquires CellTran: augmenting the bag of 'goodies' Oct 29, 2008 York Pharma (YRK.L) - acquisition of the Solvay product line is a company-transforming event Oct 17, 2008 \| Click for PDF York Pharma (YRK.L) - acquires anti-infective topical derm line from Solvay Jul 07, 2008 York Pharma (YRK.L) - interims announced: some progress but still waiting for Abasol May 28, 2008 York Pharma (YRK.L) - trading update: revenues anticipated to be ahead of expectations Apr 09, 2008 York Pharma (YRK.L) - acquisition of DDL is transformational Jan 14, 2008 \| Click for PDF York Pharma (YRK.L) - preliminary results Nov 23, 2007 York Pharma (YRK.L) - York refines Abagel formulation, files patents for fungal nail infections Oct 30, 2007 York Pharma (YRK.L) - York Pharma request approval for early Phase IIb trial of SabarepTM Oct 22, 2007 York Pharma (YRK.L) - acquisition of specialist dermatological marketer fits “hand in glove” Oct 12, 2007 York Pharma (YRK.L) - 2007 should bring a flurry of milestone achievements Jun 27, 2007 \| Click for PDF York Pharma (YRK.L) - acquisition adds interesting technologies Apr 25, 2007 \| Click for PDF York Pharma (YRK.L) - trading update reinforces sense of progress Mar 28, 2007 \| Click for PDF York Pharma (YRK.L) - update after preliminary results Nov 28, 2006 \| Click for PDF York Pharma (YRK.L) - a second shot at the Big Prize Nov 07, 2006 \| Click for PDF Disclaimer Objective Capital is a provider of corporate research. Our research reports provide information, analysis, and estimates and may reference our opinion on the value of highlighted companies. Objective Capital is not registered by any financial authority, and does not provide or purport to provide investment advice or recommendations of any description. The information in this report is designed to present the opinion of Objective's analysts and what they believe to be the objective prospects of the highlighted company. Where reference is made to estimates of value or relative value of a specific company these are based on standard analysis assuming an "average" investor. There is no guarantee that these estimates are reliable or will eventuate. They should not be relied upon in forming specific investment decisions and readers should seek advice specific to their situation and investment requirements from a person authorized under the Financial Services and Markets Act 2000, before entering into any investment agreement. Objective Capital's detailed reports are only available to ordinary business investors, market counterparties, high net-worth and sophisticated individual investors. This report does not constitute an offer or invitation to purchase or acquire any shares in any company or any interest therein, nor shall it form the basis of any contract entered into for the sale of shares in any company. The information in this report is believed to be correct, but its accuracy or completeness cannot be guaranteed. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Objective Capital (including its Directors, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, subject to restrictions imposed by internal rules. Objective Capital and its analysts are bared from trading in the shares of companies on which Objective Capital provides coverage. You are reminded that the value of shares in any company may go up or down. Past performance is not necessarily a guide to future performance. By accessing this report, you confirm that you have read and accepted this disclaimer. If you are in any doubt as to whether you are able to access this report from your jurisdiction please consult with your financial advisors before continuing.


	SIGN UP NOW FOR OBJECTIVE'S STOCK RESEARCH - IT'S FREE! Objective, Independent, Experienced. Research you can trust!

	Yes! Subscribe me for the latest stock research from Objective.


	Email address

	My Password

	My information:
	First Name
	Family Name
	Title:

	Job title:
	Job function:
	Industry:
	I am a:
	To receive occasional printed reports complete your mailing address:
	Company Name (if any)
	Address


	City
	Postcode/Zip
	Country


	Please Read Objective's Terms of Use.




	Colt Resources (COLT.CNQ) - Armamar Meda concession showing good potential Mar 13, 2009 \| Previous Reports NioGold Mining Corp (NOX.V) - valuation robust despite recession and sector meltdown Mar 10, 2009 \| Previous Reports Bridge BioResearch (private) - with some glimmer of efficacy, and safety already in evidence, clinical validation could offer lucrative returns Dec 03, 2008 \| Previous Reports e-Therapeutics (ETX.L) - ‘success-predictive’ drug discovery may be the key to new treatment horizons Nov 18, 2008 \| Previous Reports Great Western Minerals (GWG.V) - pressing ahead with mine-to-market strategy Nov 07, 2008 \| Previous Reports LiDCO (LID.L) - half year results show early signs of being on track Oct 30, 2008 \| Previous Reports Sofame Technologies (SDW.V) - reducing costs, curbing fuel usage and carbon reduction is a powerful combination Oct 29, 2008 \| Previous Reports Great Western Minerals (GWG.V) - pressing ahead with mine-to-market strategy Nov 07, 2008 \| Previous Reports LiDCO (LID.L) - half year results show early signs of being on track Oct 30, 2008 \| Previous Reports Sofame Technologies (SDW.V) - reducing costs, curbing fuel usage and carbon reduction is a powerful combination Oct 29, 2008 \| Previous Reports York Pharma (YRK.L) - acquisition of the Solvay product line is a company-transforming event Oct 17, 2008 \| Previous Reports Albania - revisiting old frontiers Oct 08, 2008 \| Previous Reports Balkan Resources (private) - exploration junior with sharp focus on Albanian Oct 08, 2008 \| Previous Reports OCCASIONAL PAPERS Albania - revisting old frontiers October, 2008 The rise of independent research (IR Magazine) March, 2006 Presentation to 2005 AIM Conference Sept 26, 2005 The Role of Sponsored Research June 22, 2005 Objective's Corporate Brochure July 01, 2004

Objective Capital's Contact Information
Partnership, sales and product inquiries: marketing@objectivecapital.co.uk
Media services and conference requests: PR@objectivecapital.co.uk
Subscription and customer service issues: service@objectivecapital.co.uk
Comments or opinions on our analysis: analysis@objectivecapital.co.uk

11-12 Tokenhouse Yard, London EC2R 7AS, United Kingdom
ph +44-(0)870-080 2965 fax +44-(0)870-116 0839